BOLDRINI, VALENTINA
BOLDRINI, VALENTINA
Medicina Sperimentale e Clinica
A safety evaluation of ruxolitinib for the treatment of polycythemia vera
2024 Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry
2025 Guglielmelli, Paola; Ghirardi, Arianna; Carobbio, Alessandra; Masciulli, Arianna; Morrone, Lucrezia; Mora, Barbara; Rumi, Elisa; Triguero, Ana; Finazzi, Maria C.; Pettersson, Helna; Boldrini, Valentina; Vanni, Daniele; Rambaldi, Alessandro; Passamonti, Francesco; Alvarez‐Larràn, Alberto; Andreasson, Bjorn; Vannucchi, Alessandro M.; Barbui, Tiziano
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy
2023 Atanasio, A; Vanni, A; Maggi, L; Pilerci, S; Mazzoni, A; Capone, M; Crupi, F; Cicogna, P; Boldrini, V; Tekle, S; Colao, M G; Borella, M; Paoli, C; Rossolini, G M; Vannucchi, A M; Annunziato, F; Guglielmelli, P
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
2022 Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A safety evaluation of ruxolitinib for the treatment of polycythemia vera | 2024 | Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola | |
Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry | 2025 | Guglielmelli, Paola; Ghirardi, Arianna; Carobbio, Alessandra; Masciulli, Arianna; Morrone, Lucrezia; Mora, Barbara; Rumi, Elisa; Triguero, Ana; Finazzi, Maria C.; Pettersson, Helna; Boldrini, Valentina; Vanni, Daniele; Rambaldi, Alessandro; Passamonti, Francesco; Alvarez‐Larràn, Alberto; Andreasson, Bjorn; Vannucchi, Alessandro M.; Barbui, Tiziano | |
Humoral and cellular responses after third dose of SARS-CoV-2 vaccine in myeloproliferative neoplasms patients on ruxolitinib therapy | 2023 | Atanasio, A; Vanni, A; Maggi, L; Pilerci, S; Mazzoni, A; Capone, M; Crupi, F; Cicogna, P; Boldrini, V; Tekle, S; Colao, M G; Borella, M; Paoli, C; Rossolini, G M; Vannucchi, A M; Annunziato, F; Guglielmelli, P | |
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis | 2022 | Guglielmelli P, Irushani Vanderwert F, Romagnoli S, Coltro G, Loscocco GG, Mannelli F, Calabresi L, Gentili G, Rotunno G, Bartalucci N, Boldrini V, Sant'Antonio E, Tarantino D, Pieraccioli M, Vannucchi AM |